Comparative Pharmacology
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus ZYRTEC ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus ZYRTEC ALLERGY.
KETOTIFEN FUMARATE vs ZYRTEC ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
Selective peripheral histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
5–10 mg orally once daily; maximum dose 10 mg/day.
None Documented
None Documented
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Terminal elimination half-life is approximately 8.3 hours (range 6–10 hours) in healthy adults, prolonged to 20–25 hours in patients with renal impairment (CrCl < 40 mL/min). No significant difference in elderly vs. young adults with normal renal function.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; approximately 10% is excreted in feces via biliary route. Total renal excretion includes both parent drug and metabolites, with cetirizine largely unchanged.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine